Abbvie Inc.

Abbvie Deutschland Gmbh and Co Kg

Abbvie Ireland Unlimited Company

Peter Hoelig

Jonathan Miller

Yi Gao

Bernd Liepold

Thomas Kessler

Eric Allen Schmitt

Yi Shi

Carl M Knable

Ping Gao

Nancy E Sever

Mark Costello

John B Morris

Drazen Kostelac

Rajeev Gokhale

Mirko Pauli

Karin Rosenblatt

Anna Moosmann

Fatih Durak

Ping Tong

Yeshwant D Sanzgiri

David J Lindley

Susan George

Esther Birtalan

Esther Roesch

Esther RÖSCH

A pro-apoptotic solid dispersion comprises, in essentially non-crystalline form, a Bcl-2 family protein inhibitory compound of Formula I as defined herein, dispersed in a solid matrix that comprises (a) a pharmaceutically acceptable water-soluble polymeric carrier and (b) a pharmaceutically acceptable surfactant. A process for preparing such a solid dispersion comprises subjecting to elevated temperature the compound of Formula I, the water-soluble polymeric carrier and the surfactant, to provide an extrudable semi-solid mixture; extruding the semi-solid mixture; and cooling the resulting extrudate to provide a solid matrix comprising the polymeric carrier and the surfactant and having the compound dispersed in essentially non-crystalline form therein. The solid dispersion is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer or an immune or autoimmune disease.

Melt-extruded solid dispersions containing an apoptosis-inducing agent

The present disclosure relates to solid dosage forms comprising antiviral compounds and methods of using such dosage forms to treat antiviral infection.

Solid antiviral dosage forms

Growing community of inventors

Waechtersbach, Germany

Peter Hoelig